Cancer Highlights Subscription

Cancer Highlights™ is BioSeeker Group’s flagship decision support tool, for portfolio assessment and planning of cancer drug development.

Here you can subscribe to the Cancer Highlights publication series, saving 65-75% compared to a normal single copy price.

A subscription consists of eight (8) consecutive reports from a rolling update of 14 different Cancer Focus Areas.

Your subscription will commence with the latest report available and automatically end after eight (8) publications and you will be notified about making a renewal. BioSeeker publishes new reports every six weeks and these will be immediately delivered to your inbox in PDF format.

To subscribe for a Site License, just select a quantity of 2 in the order box above. For a Global License, select a quantity of 3.

Key Benefits of Cancer Highlights:

Cancer Highlights™ serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning in oncology by:

• Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

• Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

• Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

• Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

• Supporting development of integrative molecule, pathway and disease area strategies

• Integrating knowledge to help you to consider the therapeutic target for the highest therapeutic outcome and return on investment

Learn more about the Cancer Highlights publication series by clicking here.